ondansetron has been researched along with diclofenac in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| McQuay, HJ; Moore, RA | 1 |
| Broome, IJ; Girgis, Y; Raj, N; Robb, HM; Wardall, GJ | 1 |
| Canda, E; Coşkun, F; Ergene, U; Fowler, J; Kirkali, Z; Pekdemir, M | 1 |
| Bagshaw, O; Rawlinson, E; Skone, R; Thillaivasan, A; Walker, A | 1 |
| Al-Huniti, N; Bui, KH; Cheung, SYA; Johnson, TN; Li, J; Xu, H; Zhou, D; Zhou, W | 1 |
| Ameri, A; Doostmohammadi, M; Forootanfar, H; Ghaseminejad, A; Jafari, E; Rahimi, HR; Salimi, A; Shakibaie, M | 1 |
2 review(s) available for ondansetron and diclofenac
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Postoperative analgesia and vomiting, with special reference to day-case surgery: a systematic review.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Codeine; Dextropropoxyphene; Diclofenac; Humans; Ibuprofen; Morphine; Ondansetron; Pain Measurement; Pain, Postoperative; Postoperative Nausea and Vomiting; Randomized Controlled Trials as Topic; Reproducibility of Results; Tramadol; Transcutaneous Electric Nerve Stimulation; Treatment Outcome | 1998 |
3 trial(s) available for ondansetron and diclofenac
| Article | Year |
|---|---|
The use of tramadol following day--case oral surgery.
Topics: Adult; Ambulatory Surgical Procedures; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Molar, Third; Ondansetron; Pain, Postoperative; Postoperative Nausea and Vomiting; Prospective Studies; Tooth Extraction; Tramadol | 1999 |
Ondansetron versus diclofenac sodium in the treatment of acute ureteral colic: a double blind controlled trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colic; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Ondansetron; Pain Measurement; Ureteral Diseases | 2001 |
A randomised controlled trial of two analgesic techniques for paediatric tonsillectomy*.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Anesthetics, Inhalation; Anesthetics, Intravenous; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Child; Child, Preschool; Codeine; Dexamethasone; Diclofenac; Double-Blind Method; Female; Fentanyl; Humans; Male; Methyl Ethers; Ondansetron; Pain Measurement; Pain, Postoperative; Postoperative Nausea and Vomiting; Propofol; Sample Size; Sevoflurane; Tonsillectomy | 2011 |
13 other study(ies) available for ondansetron and diclofenac
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
Topics: Acetates; Analgesics, Opioid; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Bronchodilator Agents; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Esomeprazole; Histamine H1 Antagonists, Non-Sedating; Humans; Infant; Infant, Newborn; Itraconazole; Lansoprazole; Loratadine; Models, Biological; Ondansetron; Pharmaceutical Preparations; Pharmacokinetics; Proton Pump Inhibitors; Quinolines; Serotonin Antagonists; Sufentanil; Sulfides; Theophylline; Tramadol | 2018 |
Ondansetron enhanced diclofenac-induced nephrotoxicity in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catalase; Diclofenac; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Kidney; Mice; Ondansetron; Serotonin Antagonists; Superoxide Dismutase | 2019 |